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Plasma a2 macroglobulin is increased in nephrotic patients as a
result of increased synthesis alone.
Background. a2 Macroglobulin (a2M), a protease inhibitor, is
often increased in plasma of patients with the nephrotic syn-
drome. Although it has been speculated that synthesis is in-
creased, no direct measurements have been performed.
Methods. a2M synthesis in both normal subjects (N 5 4) and
nephrotic patients (N 5 7) were measured using endogenous
labeling with 13C valine in order to establish the mechanism of
increased plasma level in the nephrotic syndrome and the rela-
tionship between a2M synthesis rate and plasma concentration
over a wide range of plasma concentration values. A primed (15
mmol/kg)/continuous (15 mmol/kg/hr) infusion was administered
for six hours. Blood samples were collected at different intervals
and at each time point a2M was isolated from EDTA plasma
using immunoprecipitation and SDS-polyacrylamide gel electro-
phoresis (PAGE). Care was taken to ensure that the a2M used for
combustion had not been subjected to proteolysis. The rate of
appearance of 13C valine derived from the isolated a2M was
measured by gas chromatography combustion isotope ratio mass
spectrometry.
Results. Plasma a2M was significantly elevated in nephrotic
subjects (3.13 6 0.33 g/liter) versus controls (1.64 6 0.15 g/liter;
P 5 0.012). The a2M fractional synthesis rate [(FSR), which is
equal to fractional catabolic rate (FCR) in steady state] was the
same in the two groups: 2.70 6 0.18%/day for the nephrotic
patients versus controls 2.74 6 0.21%/day. However, the a2M
absolute synthesis rate (ASR) was significantly (P 5 0.012)
increased in the patients (3.69 6 0.33 mg/kg/day) versus controls
(2.06 6 0.35 mg/kg/day). Plasma a2M concentration correlated
directly to its ASR (r2 5 0.821; P 5 0.0001; N 5 11).
Conclusions. Increased plasma a2M concentration in nephrotic
patients is therefore a result of increased synthesis alone.
Plasma a2 macroglobulin (a2M), which accounts for 3 to
5% of the total proteins, is mainly synthesized in the liver
[1], while small amounts of this protein are synthesized by
microglia as well [2]. a2M is a proteinase inhibitor [3], and
binds numerous growth factors, cytokines and hormones
[4]. The concentration in plasma is normally about 2 g/liter
and usually remains quite constant throughout life, al-
though levels gradually decline until adult age [5]. While
inherited deficiency has been reported [6, 7], a total
absence of a2M may not be compatible with life.
Increased levels of a2M are well described in patients
with the nephrotic syndrome regardless of the primary
disease [8–10], and may contribute to complications in the
nephrotic syndrome like increased plasma viscosity [11] and
decreased availability of zinc [12, 13]. On the other hand,
a2M may act as a thrombin inhibitor [10, 14]. While an
increase in synthesis of a2M in nephrotic rats has been
previously established [15], the mechanism for the increase
of a2M plasma concentration in the nephrotic humans
remains to be elucidated. One study reported that a change
in plasma volume is responsible for the increased plasma
levels of a2M in the nephrotic syndrome [16]. Since several
other studies reported normal plasma volumes in the
nephrotic syndrome [17, 18], accumulation of a2M in
plasma of the nephrotic syndrome must be a consequence
of altered metabolism rather than a consequence of plasma
volume contraction.
Once acted upon by a protease, a2M changes conforma-
tion and is cleared rapidly by the a2M receptor [19].
Recently, it has been shown that the a2M receptor is
identical to the low density lipoprotein receptor mediated
protein (LRP) [20]. We have previously established that
increased very-low density lipoprotein (VLDL) is a conse-
quence of decreased clearance in nephrotic patients [21].
Numerous studies implied that LRP/a2M receptor plays a
role in the metabolism of apo E containing lipoproteins like
VLDL [22, 23]. If the decreased clearance of VLDL is a
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consequence of alteration in the LRP, this could also result
in a reduced uptake of a2M. On the other hand, there could
be an increase in synthesis due to the increased hepatic
response.
The aim of the present study was to measure the
synthesis rate of a2M in patients with the nephrotic syn-
drome and compare them with measurements in a control
group using an endogenous labeling with [13C] valine.
METHODS
Subjects and protocol
Seven patients (six with a membranous glomerulonephri-
tis and one minimal change disease) were recruited from
the clinic of nephrology and hypertension at the University
Hospital Utrecht. Five were male. The mean age was 49 6
three years. They received no medication except diuretics.
Four healthy control subjects were also studied. Two were
male and the mean age of the control group was 30 6 1
year. The patients and volunteers agreed to participate
after informed consent in accordance with the Helsinki
Declaration of Human Rights. The study was approved by
our Institutional Ethical Committee for Studies in Humans.
One day before the infusion study, the subjects collected
24-hour urine samples that were analyzed for protein and
albumin.
The infusion protocol has been described in detail pre-
viously [17] with some minor modifications. Briefly, a
primed (15 mmol/kg)/continuous (15 mmol/kg/hr) infusion
of 13C valine was administered for six hours. Blood samples
were drawn through a second intravenous catheter in the
contralateral arm into EDTA (10 cc) containing tubes at
baseline and at t 5 4, 4.5, 5, 5.5 and 6 hours. Samples were
kept on ice (maximum 1 hr) until plasma was separated by
centrifugation (20 min, 3000 rpm, 4°C). The plasma was
immediately stored at 280°C. Experiments were done in
the fasted state and subjects were only allowed to drink
water during the tracer infusions.
Twenty-two patients (including the seven who were
subjected to the infusion protocol) with the nephrotic
syndrome were screened for 24 hour proteinuria, plasma
albumin and plasma a2M concentration. Four were female
and the mean age was 45 6 9 years (range 24 to 63 years).
Histologically proven diagnoses were: membranous glo-
merulopathy (N 5 11), minimal change disease (N 5 6),
mesangial proliferative (N 5 1), membranoproliferative
glomerulonephritis (N 5 1), and focal sclerosis (N 5 3).
They received no medication except diuretics.
Materials
L-[1-13C] valine (MassTrace, Woburn, MA, USA) was
dissolved in sterile 0.9% saline and sterilized through a 0.22
mm filter. The rabbit anti-human a2M was obtained from
Cappel (ICN Pharmaceuticals, OH, USA). The a2M anti-
body was dissolved in aqua-dest. All electrophoretic re-
agents and the electrophoretic apparatus (mini protean II)
were from Bio-Rad (Hercules, CA, USA).
Chemical measurements
Urea, creatinine, total protein and albumin were mea-
sured with standard laboratory methods on an Ektachem
950 (Johnson & Johnson, Clinical Diagnostics, NY, USA).
Proteinuria and albuminuria were measured with standard
laboratory methods on a Hitachi-911 (Boehringer, Mann-
heim, Germany). The colloid osmotic pressure (COP) was
measured using a 4400 colloid osmometer (Wescor Inc.,
Logan, UT, USA). a2M was measured using a routine
nephelometric assay (Behringwerke AG, Marburg, Germa-
ny).
Isolation and purification of a2 macroglobulin from
plasma
a2Macroglobulin was isolated from EDTA plasma by
immunoprecipitation and purified by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis according to a
method of Jahoor et al [24]. Briefly, varying amounts of
EDTA-plasma were incubated with 200 ml of antibody (6
mg/ml). This mixture was pipetted into a small tube and the
volume was made up to 1.0 ml with a solution of 0.15 M
NaCl containing 0.5 mM thimerosal (BDH, Limited, Poole,
England, UK). This solution was vortexed and incubated
for one hour at 25°C and then for 48 hours at 4°C. After
incubation, the tubes were centrifuged (5000 3 g, 20 min,
room temperature) to precipitate the a2M antibody com-
plex. After removing the supernatant, the a2M antibody
precipitates were washed three times with 1.0 ml of 0.15 M
NaCl and dissolved in 35 ml of sample buffer (0.187 M Tris,
0.104 M sodium dodecyl sulfate, 3.26 M glycerol, 0.85 M
mercaptoethanol, pH 6.8) containing 0.03% (wt/vol) bro-
mophenol blue. The b-mercaptoethanol was added to the
sample buffer just prior to use. The mixture was heated for
five minutes at 100°C and then cooled. After centrifugation
(5 min, 850 3 g), samples were loaded on a 4.5% SDS
polyacrylamide gel. Controls on each gel included a wide
range protein standard (Novex, San Diego, CA, USA), an
a2M standard and a reduced a2M antibody. The gels were
electrophoresed embedded in an ice bath in 25 mM Tris,
192 mM glycine buffer (pH 8.3) containing 3.5 mM SDS at
100 V constant, till the bromophenol blue marker ran off
the edge of the gel plates. The gels were stained for one
hour, using Coomassie Brilliant Blue R-250 in 10% (wt/vol)
acetic acid and 40% (wt/vol) methanol and destained with
two changes of a solution containing 10% acetic acid and
40% methanol. The bands corresponding to the desired
a2M fragment (180 kD) were excised from the polyacryl-
amide gels, hydrolyzed and further purified by cation-
exchange chromatography [17].
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Isolation of amino acids from plasma
Plasma amino acids were isolated from 0.75 ml plasma by
cation exchange chromatography [17]. Derivatization was
done according to the method of Husˇek [25].
Measurement of stable isotope enrichment
The ratios of tracer/tracee valine (13/12C) into plasma and
into a2M were measured by gas chromatography mass
spectrometry (GC/MS) and gas chromatography combus-
tion isotope ratio mass spectrometry, respectively (GC/C/
IRMS), as described in detail previously [19].
Calculations of a2 macroglobulin synthesis rates
a2Macroglobulin synthesis was calculated as a fractional
synthesis rate (FSR) (%/day). The FSR was calculated by
linear regression analysis. The slope was calculated using
the tracer/tracee ratio curve of a2M of the last two hours (5
time points) of constant infusion.
FSR 5 @~change in tracer/tracee ratio of a2M/time#/
~tracer/tracee ratio of plasma valine!
The absolute synthesis rate (ASR), which is the amount
of protein synthesized per day, was calculated as the
product of the FSR and the plasma pool [plasma volume
(0.045 liter/kg) 3 plasma concentration]. To adjust for
different body weights, the ASR is expressed per kg body
wt.
Statistical analysis
Data are expressed as means 6 SEM. The significance of
differences was assessed by t-test. If normality test or equal
variance test failed, a Mann-Whitney rank sum test was
performed. Correlations were performed by Spearman
rank order correlation or by linear regression analysis.
RESULTS
Protein measurements
Plasma total protein concentration, albumin concentra-
tion and COP were significantly decreased in nephrotic
patients (Table 1), while plasma a2M concentration was
increased by approximately twofold (Table 2; P 5 0.012).
The mean urinary protein excretion was 11.0 6 2.4 g/day
and the mean urinary albumin excretion was 8.3 6 2.0 g/day
in nephrotic patients. In the group of 22 patients, plasma
albumin concentrations (23.8 6 0.8 g/liter) were signifi-
cantly (P , 0.0001) decreased while proteinuria (8.0 6 0.9
g/day) and a2M plasma concentrations (4.15 6 0.41 g/liter)
were significantly increased (respectively P , 0.0001 and
P 5 0.0032).
Isolation and purification of a2 macroglobulin from
plasma
After precipitation of plasma with antihuman a2M, a
clear pellet was visible and no a2M was detectable in the
supernatant. a2M with a molecular weight of 720 kD is
composed of four identical subunits with a molecular
weight of 180 kD each. If the protein is bound to any of
several proteases, the 180 kD subunit is split into two 90 kD
fragments, as seen on SDS-PAGE under reducing condi-
tions [26–29]. Figure 1 (lane 4) shows the SDS-PAGE
pattern of the a2M immunoprecipitate from EDTA
plasma. Reduced a2M revealed a major fragment of 180
kD. A Western blot confirmed the identity of the 180 kD
band (data not shown).
Synthesis rate of a2 macroglobulin
Figure 2 shows the percentage enrichment of valine in
the 180 kD subunit in relation to the enrichment in plasma
valine. Because of the slow turnover rate of a2M, we used
the amount of 13C valine incorporated during the last two
hours of infusion for measuring synthesis rates. In this time
period, the modest increase in tracer/tracee ratio of a2M
could be measured by using GC/C/IRMS accurately, since
precision of this instrument is high.
The fractional synthesis rate (FSR) of a2M was not
significantly different between the groups: 2.70 6 0.18%/
day for the nephrotic patients versus 2.74 6 0.21%/day for
the controls, respectively (Table 2). The absolute synthesis
rate however was significantly (P 5 0.012) increased in
patients (3.69 6 0.33 mg/kg/day) versus controls (2.06 6
0.35 mg/kg/day; Table 2).
Table 1. Clinical characteristics of nephrotic patients and controls
Patients
(N 5 7)
Controls
(N 5 4) P value
Gender male/female 5/2 2/2
Weight kg 81.7 6 3.6 83.7 6 8.0 NS
Body mass index kg/m2 26.2 6 1.4 25.6 6 2.5 NS
Plasma urea mmol/liter 7.7 6 1.3 3.8 6 0.5 NS
Plasma creatinine mmol/liter 110 6 11 78 6 6 NS
Total protein g/liter 44 6 1 64 6 3 , 0.0001
Plasma albumin g/liter 21.9 6 0.9 37.4 6 1.3 , 0.0001
Plasma COP mm Hg 11.3 6 0.7 24.5 6 0.8 , 0.0001
Proteinuria g/day 11.0 6 2.4 , 0.1 , 0.0001
Albuminuria g/day 8.3 6 2.0 , 0.1 , 0.0001
Values are expressed as mean 6 SEM, NS is not significant.
P values were determined by t-test. If normality test or equal variance
test failed, a Mann-Whitney rank sum test was performed.
Table 2. a2Macroglobulin plasma concentration and its fractional
catabolic rate (FCR) and absolute synthesis rate (ASR) in nephrotic
patients and controls
Patients
(N 5 7)
Controls
(N 5 4) P value
Plasma a2M g/liter 3.13 6 0.33 1.64 6 0.15 0.012
FCR % day 2.70 6 0.18 2.74 6 0.21 NS
ASR mg/kg/day 3.69 6 0.33 2.06 6 0.35 0.012
Values are expressed as mean 6 SEM.
P values were determined by t-test.
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Correlations
Considering the data in controls and patients together,
plasma concentration of a2M was directly correlated to its
ASR (Fig. 3; r2 5 0.821; P 5 0.0001; N 5 11). Within the
patient group (N 5 7), there was also a correlation between
plasma concentration of a2M and its ASR (r
2 5 0.656; P 5
0.027; N 5 7), while there was no correlation between
plasma a2M concentration and plasma albumin concentra-
tion (P 5 0.54), or proteinuria (P 5 0.30). However, if we
expanded the number of patients to 22 a significant rela-
tionship between plasma a2M concentration and both
proteinuria (P 5 0.015) and plasma albumin concentration
(P 5 0.028) was found.
DISCUSSION
In this study, we have shown that the increase of a2M in
the nephrotic syndrome is a direct result of increased
synthesis with no contribution by a change in FSR. At
steady state FSR is identical to fractional catabolic rate
(FCR), and although measurements of a2M FCR were not
made directly, it would be reasonable to assume that a
decrease in the FCR of a2M plays no significant role in
causing an increase in its plasma concentration in nephrotic
humans.
An increase in synthesis of a2M is in agreement with
observations in nephrotic rats [15]. In addition, plasma a2M
concentration and synthesis rate are also increased in rats
with hereditary analbuminemia, although to a lesser extent
[15].
Although we have now established that the increase in
plasma a2M concentration in the nephrotic syndrome is
due to increased synthesis alone, the possible mechanism
responsible for signaling the increased rate of synthesis is
still unknown. In the patient group that was subjected to
the infusion study, no relationship was found between the
a2M concentration and urinary protein loss (P 5 0.30; N 5
7), while this relationship becomes significant when we
expanded the patient group (P 5 0.015; N 5 22). This
suggests that there is a loss of some regulatory protein in
nephrotic urine. However, such a hypothesis would not
explain the increased a2M levels in plasma of hereditary
analbuminemia. Therefore, as an alternative one has to
consider that synthesis is stimulated in response to either
reduced albumin levels or reduced plasma COP. This is
further supported by a significant relationship between
plasma albumin concentration and plasma a2M concentra-
tion (P 5 0.028; N 5 22).
We are not aware of any report in literature on rates of
synthesis of a2M. The only kinetic data available, with
regard to this protein, are decay studies using 125I labeled
a2M. The reported FCR (8 to 9%/day) in normal subjects
[16] is greater than we report in this study. There are
several reasons for this apparent discrepancy. Radiolabel-
ing of proteins may introduce changes in conformation that
cause a non-physiologic increase in their rate of removal.
Fig. 1. SDS-PAGE (4.5%) pattern of the a2macroglobulin (a2M) immu-
noprecipitate from plasma after direct treatment with anti sera. Lane 1:
a2M standard, Lane 2: antibody, Lane 3: wide range protein standard (200
kD, 116 kD, 97 kD), Lane 4: a2M precipitate.
Fig. 2. Percentage enrichment of valine in the 180 kD subunit in relation
to the enrichment in plasma valine between four and six hours of 13C
valine infusion. Shown is the mean 6 SEM curve for both nephrotic
patients (E; N 5 7) and controls (F; N 5 4).
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a2M is an exceptionally unstable protein, denatured easily
by freezing and thawing and easily altered by proteases and
neucleophiles. Clearance was measured of the whole a2M
particle which includes the complexed form with proteases,
which is subject to a rapid clearance from the circulation by
macrophages. On the other hand, measurements of synthe-
sis using stable isotope technology require the specific
enrichment of the precursor pool (valine tRNA pool). In
this study, we used tracer/tracee ratio in plasma valine that
overestimates the real precursor pool by 30% and thereby
underestimates the FSR.
Increased synthesis and thereby increased concentration
of a2M has potential physiological consequences. Besides
albumin [30], a2M also binds zinc. The tight binding of a2M
to zinc [31, 32] may make zinc less biologically available
than it would otherwise be [33]. a2M may also contribute to
an increased viscosity that may lead to an increased cardio-
vascular disease [11]. On the other hand, increased levels of
a2M could have a potentially beneficial role by action as an
inhibitor of thrombin [10, 14]. Plasma total anti thrombin
activity is increased in patients with the nephrotic syndrome
[10], although anti-thrombin III (AT III) plasma levels
have been reported to be decreased in nephrotic patients
[9, 34, 35], since AT III, of a molecular weight close to that
of albumin, is lost in the urine. Although it has been shown,
by in vitro studies, that with respect to AT(III) the role of
a2M as a thrombin inhibitor appears to be of little rele-
vance [36, 37], this may not be true for pathophysiological
conditions like the nephrotic syndrome.
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APPENDIX
Abbreviations used in this article are: a2M, a2 macroglobulin; ASR,
absolute synthesis rate; AT III, anti-thrombin III; 13C/12C, tracer/tracee
valine; COP, colloid osmotic pressure; FCR, fractional catabolic rate;
FSR, fractional synthesis rate; GC/C/IRMS, gas chromatography combus-
tion isotope ratio mass spectrometry; GC/MS, gas chromatography mass
spectrometry; LRP, low-density lipoprotein receptor-mediated protein;
PAGE, polyacrylamide gel electrophoresis; VLDL, very low density
lipoprotein.
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